The interval from surgery to chemotherapy in the treatment of advanced epithelial ovarian carcinoma

European Journal of Surgical Oncology

Volumn 32, Issue 5, 2006, Pages 588-591

  Rosa, D D ^a   Clamp, A ^a   Mullamitha, S ^a   Ton, N C ^a   Lau, S ^a   Byrd, L ^a   Clayton, R ^b   Slade, R J ^a   Kitchener, H C ^b   Shanks, J H ^a   Wilson, G ^b   McVey, R ^b   Hasan, J ^a   Swindell, R ^a   Jayson, G C ^a  

^a CHRISTIE HOSPITAL   (United Kingdom)

^b ST MARY S HOSPITAL   (United Kingdom)

Author keywords

Advanced ovarian cancer; Chemotherapy; Ovarian cancer; Stage III ovarian cancer; Surgery

Indexed keywords

ANTINEOPLASTIC AGENT; CA 125 ANTIGEN; CARBOPLATIN; PLATINUM DERIVATIVE;

ABDOMINAL HYSTERECTOMY; ADULT; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; CYTOREDUCTIVE SURGERY; FEMALE; GYNECOLOGIC SURGERY; HUMAN; MAJOR CLINICAL STUDY; MULTIVARIATE ANALYSIS; OVARY CARCINOMA; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; PROGNOSIS; SALPINGOOOPHORECTOMY; STATISTICAL SIGNIFICANCE; SURGICAL TECHNIQUE; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CA-125 ANTIGEN; CARBOPLATIN; CARCINOMA; CHEMOTHERAPY, ADJUVANT; FALLOPIAN TUBES; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYSTERECTOMY; MIDDLE AGED; NEOPLASM STAGING; NEOPLASM, RESIDUAL; OMENTUM; OVARIAN NEOPLASMS; OVARIECTOMY; PLATINUM COMPOUNDS; PROGNOSIS; SURVIVAL ANALYSIS; TIME FACTORS; TREATMENT OUTCOME;

EID: 33646763194     PISSN: 07487983     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejso.2006.02.013     Document Type: Article

References (23)

1. Flynn P.M., Paul J., and Cruickshank D.J. Does the interval from primary surgery to chemotherapy influence progression-free survival in ovarian cancer?. Gynecol Cancer 86 (2002) 354-357
2. Richardson G.S., Scully R.E., Nikrui N., and Nelson J.H. Common epithelial cancer of the ovaries (first of two parts). N Engl J Med 312 (1985) 415-424
3. Sorbe B. Prognostic importance of the time interval from surgery to chemotherapy in treatment of ovarian carcinoma. Int J Gynecol Cancer 14 (2004) 788-793
4. Gadducci A., Sartori E., Landoni F., Zola P., Maggino A., et al. Relationship between time interval from primary surgery to the start of taxane-plus platinum-based chemotherapy and clinical outcome of patients with advanced epithelial ovarian cancer: results of a multicenter retrospective Italian study. J Clin Oncol 23 (2005) 751-758
5. Warwick J., Kehoe S., Earl H., Luesley D., Redman C., and Chan K.K. Long-term follow-up of patients with advanced ovarian cancer treated in randomised clinical trials. Br J Cancer 72 (1995) 1513-1517
6. Fisher B., Gunduz N., and Saffer E.A. Influence of the interval between primary tumor removal and chemotherapy on kinetics and growth of metastases. Cancer Res 43 (1983) 1488-1492
7. Bell R.S., Roth Y.F., Gebhardt M.C., Bell D.F., Rosenberg A.E., Mankin H.J., et al. Timing of chemotherapy and surgery in a murine osteosarcoma model. Cancer Res 48 (1988) 5533-5538
8. Berg J., Gebhardt M.C., and Rand W.M. Effect of timing of postoperative chemotherapy on survival of dogs with osteosarcoma. Cancer 79 (1997) 1343-1350
9. Buzdar A.U., Smith T.L., Powell K.C., Blumenschein G.R., and Gehan E.A. Effect of timing of initiation of adjuvant chemotherapy on disease-free survival in breast cancer. Breast Cancer Res Treat 2 (1982) 163-169
10. Pronzato P., Campora E., Amoroso D., Bertelli G., Botto F., Conte P.F., et al. Impact of administration-related factors on outcome of adjuvant chemotherapy for primary breast cancer. Am J Clin Oncol 12 (1989) 481-485
11. Colleoni M., Bonetti M., Coates A.S., Castiglione-Gertsch M., Gelber R.D., Price K., et al. Early start of adjuvant chemotherapy may improve treatment outcome for premenopausal breast cancer patients with tumors not expressing estrogen receptors. The International Breast Cancer Study Group. J Clin Oncol 18 (2000) 584-590
12. Clark T.G., Stewart M.E., Altman D.G., Gabra H., and Smyth J.F. A prognostic model for ovarian cancer. Br J Cancer 85 (2001) 944-952
13. Jacobs I., and Bast Jr. R.C. The CA 125 tumour-associated antigen: a review of the literature. Hum Reprod 4 (1989) 1-12
14. van der Burg M.E., Lammes F.B., van Putten W.L., and Stoter G. Ovarian cancer: the prognostic value of the serum half-life of CA125 during induction chemotherapy. Gynecol Oncol 30 (1988) 307-312
15. Hogberg T., and Kagedal B. Serum half-life of the tumor marker CA 125 during induction chemotherapy as a prognostic indicator for survival in ovarian carcinoma. Acta Obstet Gynecol Scand 69 (1990) 423-429
16. Buller R.E., Berman M.L., Bloss J.D., Manetta A., and DiSaia P.J. Serum CA125 regression in epithelial ovarian cancer: correlation with reassessment findings and survival. Gynecol Oncol 47 (1992) 87-92
17. Gadducci A., Zola P., Landoni F., Maggino T., Sartori E., Bergamino T., et al. Serum half-life of CA 125 during early chemotherapy as an independent prognostic variable for patients with advanced epithelial ovarian cancer: results of a multicentric Italian study. Gynecol Oncol 58 (1995) 42-47
18. Peters-Engl C., Obermair A., Heinzl H., Buxbaum P., Sevelda P., and Medl M. CA 125 regression after two completed cycles of chemotherapy: lack of prediction for long-term survival in patients with advanced ovarian cancer. Br J Cancer 81 (1999) 662-666
19. Tsuda H., Hashiguchi Y., Nakata S., Deguchi M., Negoro S., Ishito O., et al. The CA125 regression rate to predict overall survival differ between paclitaxel-containing regimen and nonpaclitaxel regimen in patients with advanced ovarian cancer. Int J Gynecol Cancer 12 (2002) 435-437
20. Gadducci A., Cosio S., Fanucchi A., Negri S., Cristofani R., and Genazzani A.R. The predictive and prognostic value of serum CA 125 half-life during paclitaxel/platinum-based chemotherapy in patients with advanced ovarian carcinoma. Gynecol Oncol 93 (2004) 131-136
21. Rustin G.J., Nelstrop A.E., Bentzen S.M., Piccart M.J., and Bertelsen K. Use of tumour markers in monitoring the course of ovarian cancer. Ann Oncol 10 Suppl 1 (1999) 21-27
22. Rustin G.J., Nelstrop A.E., Bentzen S.M., Bond S.J., and McClean P. Selection of active drugs for ovarian cancer based on CA-125 and standard response rates in phase II trials. J Clin Oncol 18 (2000) 1733-1739
23. Rustin G.J., Bast Jr. R.C., Kelloff G.J., Barrett J.C., Carter S.K., Niser P.D., et al. Use of CA-125 in clinical trial evaluation of new therapeutic drugs for ovarian cancer. Clin Cancer Res 10 (2004) 3919-3926